Programmed death 1 (PD-1) blocking antibodies now represent a major advance in the treatment of patients with classical Hodgkin lymphoma (cHL) who relapse after autologous stem cell transplantation (ASCT) and pre- and/or post-ASCT brentuximab vedotin or after at least three lines of therapy. However, uncertainties still remain on the optimal use of these agents in refractory Hodgkin disease. A panel of experts was convened to produce a consensus document aimed at providing practice recommendations for the optimal use of PD-1 blocking antibodies in cHL, especially on pretreatment selection and evaluation of cHL patients' response and treatment length, management of PD-1 blockade therapy-treated patients, evaluation and management of toxicity. Our hope is that these recommendations might help hematologists to improve optimal management of patients with pretreated cHL.
Keywords: Hodgkin lymphoma; checkpoint inhibitors; practice guidelines.